<DOC>
	<DOCNO>NCT02507154</DOCNO>
	<brief_summary>This study aim determine safety efficacy expand activate autologous NK cell administer cetuximab patient EGFR-positive nasopharyngeal carcinoma head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Reactivating NK Cells Treating Refractory Head Neck Cancer</brief_title>
	<detailed_description>Natural killer ( NK ) cell cytotoxic lymphocyte innate immune system responsible direct indirect cytolytic kill virally-transformed and/or cancer cell . Harnessing NK cell cancer immunotherapy therefore , provide direct cytotoxic effect cancer cell stimulate downstream adaptive anti-tumor immune response cancer . In order effect target kill tumor cell , use monoclonal antibody ( mAb ) direct NK cell target site feasible , provide specific tumor antigen identify . In nasopharyngeal Carcinoma ( NPC ) head neck squamous cell carcinoma ( HNSCC ) epidermal growth factor receptor ( EGFR ) ubiquitously express , combine NK cell therapy cetuximab ( chimeric mouse/human anti-EGFR monoclonal antibody ) direct NK cell EGFR tumor target possible . In study , seek enhance antitumor activity cetuximab treat EGFR-positive head neck cancer comb infusion activate expand autologous NK cell cetuximab . Patients select trial refractory NPC HNSCC feasible therapeutic option available . This lead-in phase I follow phase II study . The phase I study enroll 9 patient test feasibility safety combination strategy determine tolerate dose NK cell infusion ( 1x1^06/kg 1x10^7/kg NK cell ) adult EGFR positive NPC HNSCC patient . For first 3 patient , new patient enrol least 3 week treatment precede patient allow sufficient time monitor toxicity . Initial phase treatment consist 7 week cetuximab monotherapy . At week 8 , clinical evaluation do determine patient suitable continue study NK cell therapy , base severity toxicity encounter . Eligible patient undergo apheresis ( Day -10 ) harvest NK cell . The collected NK cell expand activated laboratory . During cycle 1 , cetuximab give day 1 subcutaneous IL-2 ( three time per week 2 week ) ; follow expand NK cell day 2 . The purpose IL-2 sustain activity NK cell in-vivo . Cetuximab administer weekly additional 2 week follow NK cell infusion cycle 1 . For cycle 2 3 , cetuximab monotherapy administer every 21 day . Clinical evaluation perform upon completion cycle 3 . Patients stable disease partial response allow continue second NK infusion dose per cycle 1 , follow additional 2 cycle cetuximab monotherapy ( every 21 day ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Age &gt; 21 2 . Histologically confirm diagnosis WHO type III ( undifferentiated ) EGFRpositive nasopharyngeal carcinoma EGFRpositive head neck squamous cell carcinoma ( base &gt; 80 % immunohistochemistry stain tissue biopsy ) 3 . Recurrent cancer surgically salvageable 4 . Metastatic disease ( one course palliative chemotherapy complete ) 5 . Presence measurable tumor RECIST 1.1 criterion 6 . At least two week since receipt biological therapy , chemotherapy , and/or radiation 7 . Adequate organ function : ANC ≥ 1500/µL Platelet count ≥ 100,000/µL Creatinine clearance ≥60ml/minute Total bilirubin ≤ 1.5 x upper limit normal AST ≤ 5 x upper limit normal ALT ≤ 5 x upper limit normal 8 . ECOG performance status 01 9 . Life expectancy least 60 day 1 . Treatment within last 30 day investigational drug 2 . Concurrent administration tumor therapy , include cytotoxic chemotherapy , hormonal therapy , immunotherapy 3 . Major surgery within 28 day study drug administration 4 . Active infection opinion investigator would compromise patient 's ability tolerate therapy 5 . Lactating pregnant 6 . Second primary malignancy clinically detectable time consideration study enrolment 7 . Receipt steroids time period 3 day prior expand NK cell infusion 30 day infusion ( i.e . day 3 day +30 ) . 8 . Symptomatic brain metastasis 9 . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator ; serious cardiac illness medical condition include limited : Patients dyspnea rest . History document congestive heart failure High risk uncontrolled arrhythmias Angina pectoris require medicinal product Clinically significant valvular disease Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>NK cell</keyword>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>head neck squamous cell cancer</keyword>
</DOC>